Impaired hepatic energy metabolism in rat acute pancreatitis: protective effects of prostaglandin E2 and synthetic protease inhibitor ONO 3307.
To evaluate the effects of acute pancreatitis on the energy metabolism of the liver and on the fragility of hepatic cells and subcellular organelles, we studies (1) the arterial blood ketone body ratio (BKBR) (aceto acetate/beta-hydroxy butyrate), which is in equilibrium with the free NAD+/NADH ratio in liver mitochondria; (2) the hepatic energy charge (EC) = (ATP + 1/2 ADP)/(ATP + ADP + AMP); (3) the cathepsin B leakage from hepatic lysosomes and the malate dehydrogenase leakage from hepatic mitochondria in vitro; and (4) the protective effects of prostaglandin E2 (PGE2) and a new synthetic protease inhibitor ONO 3307 on hepatic injury in acute pancreatitis induced in rats by a supramaximal dose of caerulein. Decreased BKBR and hepatic EC as well as increased hepatic lysosomal and mitochondrial fragility were observed in rats with this type of acute pancreatitis, and both PGE2 and ONO 3307 had a significant protective effect against hepatic injury in these rats, especially ONO 3307. These results suggest that impaired hepatic energy metabolism is closely related to increased hepatic lysosomal and mitochondrial fragility and that some proteases, which are derived from pancreatitis and are susceptible to inhibition by ONO 3307, seem to play an important pathological role in this liver injury induced by pancreatitis. Therefore, it is important to take care of the liver in patients with acute pancreatitis.
Hirano
T
T
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Manabe
T
T
Tobe
T
T
D020155:3-Hydroxybutyric Acid; D000090:Acetoacetates / Q000097:blood; D000208:Acute Disease; D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002401:Cathepsin B / Q000378:metabolism; D015232:Dinoprostone / Q000627:therapeutic use*; D004734:Energy Metabolism; D006146:Guanidines / Q000627:therapeutic use*; D006885:Hydroxybutyrates / Q000097:blood; D008099:Liver / Q000378:metabolism* / Q000648:ultrastructure; D008107:Liver Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008247:Lysosomes / Q000378:metabolism; D008291:Malate Dehydrogenase / Q000378:metabolism; D008297:Male; D008930:Mitochondria, Liver / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D010195:Pancreatitis / Q000150:complications / Q000378:metabolism*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains
D000090:Acetoacetates; D006146:Guanidines; D006885:Hydroxybutyrates; D011480:Protease Inhibitors; D009243:NAD; C016635:acetoacetic acid; D000244:Adenosine Diphosphate; C062836:ONO 3307; D000255:Adenosine Triphosphate; D008291:Malate Dehydrogenase; D002401:Cathepsin B; D015232:Dinoprostone; D020155:3-Hydroxybutyric Acid